MW: Molecular Weight marker reduced condition
NR: BCMA tetramer under non-reduced condition
Immobilized human BCMA-His protein tetramer (CSP-26402.M4-01) at 2 μg/mL (100 μL/well) can bind anti-human BCMA belantamab biosimilar monoclonal antibody with half maximal effective concentration (EC50) range of 1.6-6.2 ng/mL (QC tested).
Immobilized human BCMA-His protein tetramer (CSP-26402.M4-01) at 2 μg/mL (100 μL/well) can bind anti-human BCMA monoclonal antibody with half maximal effective concentration (EC50) range of 121.3-485 ng/mL (QC tested).
Immobilized human BCMA-His protein tetramer (CSP-26402.M4-01) at 2 μg/mL (100 μL/well) can bind human BAFF protein with half maximal effective concentration (EC50) range of 41-164 ng/mL (QC tested).
Flow cytometry analysis of anti-BCMA CAR expression on HEK293T cells transiently transfected with BCMA-specific scFv CAR construct. Transfected cells were stained with PE- conjugated anti-G4S linker antibody and Human BCMA Protein Tetramer His Tag (TS402-M4- 01) followed by APC-conjugated anti-His tag antibody detection. Thereafter, flow cytometry analyses were performed to detect surface expression of the anti-BCMA CAR. The purple curve represents BMCA CAR expressing cells detected by Human BCMA Protein Tetramer His Tag (TS402-M4-01) while the black curve represents no BCMA protein staining. Mock transfected cells have no binding to either anti-G4S linker antibody or Human BCMA Protein Tetramer His Tag. The histogram shows that over 95% of anti-BCMA CAR are detected by Human BCMA Protein Tetramer His Tag (TS402-M4-01) on anti-G4S linker positive cells.

Bioactive, Human BCMA Protein Tetramer, His Tag

Product Category: All Products

Product Code: CSP-26402.M4-01
Specificity: Human
Expression Host: HEK293T
Verified Applications: ELISA for BCMA-specific antibody and B-cell activating factor (BAFF) ligand protein binding assays; BCMA-specific CAR (chimeric antigen receptor) expressing cells.
Suggested Applications: SPR & BLI for BCMA-specific antibody and BAFF protein binding assays. Animal immunization, RUO.
Purity: Greater than 90% dimer form as determined by SDS-PAGE under non-reducing condition
Amino Acid Range: L2 – A54

For Research Use Only (RUO)

Add to Quote

Ready to buy now?
Email us at [email protected] and we’ll help you place your order directly.

Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4 with 10% trehalose as protectant
Shipping: Frozen Ice Packs
Storage: -20’C

Datasheet

MSDS

Human B-cell maturation antigen (BCMA) is a cell surface receptor in the TNF receptor superfamily. The recombinant BCMA tetramer protein (CSP-26402.M4-01) is a cis-homotetramer (cis-tetramer) and contains a BCMA extracellular domain (UniProt# Q02223, amino acids Leu2 – Ala54) fused with a proprietary tetramer motif followed by a His tag at the C-terminus. This tetrameric protein is expressed in HEK293T cells. The recombinant human BCMA tetramer protein is bioactive and can bind to B-cell activating factor (BAFF). It also binds BCMA-specific antibodies. This BCMA tetramer can be used as an antigen for in vitro assays including antigen-specific CAR-T detection and antibody screening, and as an immunogen for immunization to generate antibodies targeting more conformational epitopes.
Product Name: BCMA, Protein Tetramer
UniProt #: Q02223
Predicted Molecular Weight: 39 kDa
SDS PAGE Molecular Weight: The migration range of the protein dimer with glycosylation under non-reducing condition is 70 to 120 kDa on SDS-PAGE.
Protein Construct: BCMA tetramer protein contains a BCMA extracellular domainfused with a proprietary tetramer motif followed by a His tag at the C-terminus.

Background and Alternate Names

Human B-cell maturation antigen (BCMA) is a cell surface receptor in the TNF receptor superfamily. BCMA is also known as tumor necrosis factor receptor superfamily member 17 (TNFRSF17), BCM, and CD269. BCMA contains a short conserved extracellular domain at the N-terminus called the BCMA TALL-1 binding domain which binds its ligand B-cell activating factor (BAFF). BCMA is expressed primarily on B cells in the later stages of differentiation and is essential for the survival of long-lived plasma cells, however, it is significantly overexpressed in multiple myeloma cells. BCMA has also been implicated in leukemia and lymphomas which has made BCMA a crucial target for therapeutic antibodies and CAR-T therapy.

Alternate Names: tumor necrosis factor receptor superfamily member 17, TNFRSF17, BCM, CD269, TNFRSF13A, TNF receptor superfamily member 17